MAXCYTE, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M |
| Cost of revenue | $6.2M | $7.1M | $4.7M | $5.1M | $3.6M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M |
| Research and development | $20.8M | $22.2M | $23.8M | $19.5M | $15.4M |
| Operating expenses | $78.7M | $82.7M | $84.8M | $66.5M | $48.4M |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M | -$18.2M |
| Interest expense | — | — | — | — | $5,400 |
| Pretax income | -$44.6M | -$41.1M | -$37.9M | — | — |
| Income tax expense | — | — | — | — | $0 |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M | -$19.1M |
| Balance Sheet | |||||
| Cash and equivalents | $20.1M | $27.9M | $46.5M | $11.1M | $47.8M |
| Current assets | $118.4M | $171.7M | $190.2M | $252.3M | $270.4M |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Current liabilities | $14.3M | $15.8M | $17.9M | $15.4M | $15.6M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M |
| Stockholders' equity | $171.5M | $206.3M | $232.2M | $254.0M | $262.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$34.4M | -$27.6M | -$21.7M | -$14.8M | -$10.7M |
| Depreciation and amortization | $4.3M | $4.3M | $4.2M | $2.7M | $1.4M |
| Stock-based compensation | $9.2M | $13.1M | $14.0M | $11.8M | $8.0M |
| Capital expenditure | $1.8M | $1.7M | $3.7M | $18.5M | $3.8M |
| Free cash flow | -$36.2M | -$29.3M | -$25.4M | -$33.3M | -$14.5M |
| Impairments | $3.6M | $0 | $0 | $0 | $0 |
Shares outstanding 107.1M · Free float 78.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.